检索结果-南通市图书馆

The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors

Cancer Drug Resistance 2019年第2期2卷 326-334页

作者： Jasmine Cassar White perla pucci Francesco Crea School of Life Health and Chemical Sciences The Open UniversityWalton HallMilton Keynes MK76AAUK

Current cancer therapies are often associated with treatment failure and reduced patients’survival due to drug resistance.There are various mechanisms involved in the acquisition of cancer drug resistance,including the selection of advantageous mutations,overexpression of transporter proteins and epigenetic alterations.In this context,epigenetic alterations refer to chromatin-mediated regulation of gene expression that results in heritable changes in the cellular phenotype.There is an ever-growing body of evidence suggesting that epigenetic mechanisms play an important role in bringing about drug resistance in cancer cells.While the relationship between chemotherapy and epigenetics has been widely discussed,emerging evidence indicates that specific epigenetic effectors are also crucial for the development of resistance to tyrosine kinase inhibitors(TKIs).One particular gene that encodes the histone lysine demethylase KDM5A is overexpressed in several cancers.In breast cancer tissues,cells with KDM5A gene amplification were found to be more resistant to erlotinib,an inhibitor of the tyrosine kinase epidermal growth factor receptor(EGFR),when compared to cells without the same amplification.KDM5A was also shown to mediate resistance to a second EGFR inhibitor called gefitinib,in EGFR-mutant lung cancer cell lines.This evidence indicates that KDM5A could activate alternative survival pathways involved in overcoming EGFR inhibition.In line with these results,another histone demethylase(i.e.,KDM1A)promotes liver cancer cells’resistance to the TKI sorafenib.Current evidence provides a suitable rationale to consider the use of specific KDMs inhibitors to sensitize cells to tyrosine kinase targeted therapies and thus,presents an opportunity to prevent the further development of drug resistance.This review discusses the involvement of histone lysine demethylases in the development of resistance to TKI and highlights the importance to develop new cancer treatment regimens to counteract this phenomenon.

关键词： Epigenetics drug resistance cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：